Current Report Filing (8-k)
October 28 2022 - 06:07AM
Edgar (US Regulatory)
0001348362false00013483622022-10-272022-10-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported) October
27, 2022
|
LEXARIA BIOSCIENCE
CORP.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
|
000-52138
|
|
20-2000871
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
100 – 740 McCurdy Road, Kelowna, BC Canada
|
|
V1X 2P7
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(250) 765-6424
|
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
Warrants to Purchase Common Stock
|
|
LEXX
LEXXW
|
|
The Nasdaq Capital Market
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other Events
On October 27, 2022, Lexaria Bioscience Corp. (“Lexaria”) announced
the partial results from its human clinical study HYPER-H21-4 which
evaluated DehydraTECH™ processed cannabidiol (“CBD”), as a
treatment for elevated blood pressure and Stage 1- 2 hypertension
in 66 patients during a five week study. Results showed that
DehydraTECH-CBD significantly reduced the blood pressure in all
participants, including those that were concurrently using
anti-hypertensive therapies, without any serious adverse
effects.
Item 9.01 Financial Statements and
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
LEXARIA BIOSCIENCE CORP.
|
|
|
|
/s/ Chris Bunka
|
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
|
Date: October 28, 2022
|
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Jan 2023 to Feb 2023
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Feb 2022 to Feb 2023
